Enfortumab vedotin plus pembrolizumab for previously untreated locally advanced or metastatic urothelial carcinoma: a cost-effectiveness analysis

Enfortumab vedotin plus pembrolizumab for previously untreated locally advanced or metastatic urothelial carcinoma: a cost-effectiveness analysis

Background: Both the antibody–drug conjugate (ADC) enfortumab vedotin (EV) and programmed death-1 inhibitor pembrolizumab have been shown to provide survival benefits in patients previously treated with locally advanced or metastatic urothelial carcinoma (la/mUC). Cost-effectiveness is necessary to...

Full description

Saved in:
Bibliographic Details
Main Authors: Youwen Zhu, Kun Liu, Hong Zhu, Shan Li, Dan Yuan
Format: Article
Language:English
Published: SAGE Publishing 2025-01-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359241295544
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items